

Applicant : Ira Tabas
Serial No. : Not Yet Known
Filed : January 28, 2004
Page 2

In the claims:

Please amend the pending claims under the provisions of revised 37 C.F.R. §1.121 as follows.

1. (originally presented) A method for inhibiting macrophage death in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an effective amount of an amphiphilic compound or a pharmaceutically acceptable salt thereof which inhibits the intracellular transport of cholesterol within cells, wherein the transport is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit macrophage death in the subject.
2. (originally presented) A method for inhibiting atherosclerotic lesional complications in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an effective amount of an amphiphilic compound or a pharmaceutically acceptable salt thereof which inhibits the intracellular transport of cholesterol within cells, wherein the transport is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit atherosclerotic lesional complications in the subject.
- 3.-12. (canceled)
13. (originally presented) A method for inhibiting macrophage death in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an effective amount of an amphiphilic compound or a pharmaceutically acceptable salt

Applicant : Ira Tabas
Serial No. : Not Yet Known
Filed : January 28, 2004
Page 3

thereof which inhibits free cholesterol-induced death of cells in the subject by inhibiting intracellular transport of cholesterol within the cells, wherein the transport is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit macrophage death in the subject.

14. (originally presented) A method for inhibiting atherosclerotic lesional complications in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an effective amount of an amphiphilic compound or a pharmaceutically acceptable salt thereof which inhibits free cholesterol-induced death of cells in the subject by inhibiting intracellular transport of cholesterol within the cells, wherein the transport is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit atherosclerotic lesional complications in the subject.

15.-26. (canceled)

27. (originally presented) A method for inhibiting necrosis, plaque rupture and/or superficial erosion in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an effective amount of an amphiphilic compound or a pharmaceutically acceptable salt thereof which inhibits intracellular transport of cholesterol within cells, wherein the transport is from an intracellular cholesterol storage site to the endoplasmic reticulum, so as to thereby inhibit necrosis, plaque rupture and/or superficial erosion in the subject.